Dennis L. Citrin

2.7k total citations
58 papers, 1.4k citations indexed

About

Dennis L. Citrin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Dennis L. Citrin has authored 58 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 27 papers in Oncology and 22 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Dennis L. Citrin's work include Medical Imaging and Pathology Studies (16 papers), Bone health and treatments (16 papers) and Radiopharmaceutical Chemistry and Applications (15 papers). Dennis L. Citrin is often cited by papers focused on Medical Imaging and Pathology Studies (16 papers), Bone health and treatments (16 papers) and Radiopharmaceutical Chemistry and Applications (15 papers). Dennis L. Citrin collaborates with scholars based in United States, United Kingdom and Nepal. Dennis L. Citrin's co-authors include R. G. Bessent, W. R. Greig, Ignac Fogelman, John G. Turner, Iain T. Boyle, Kennedy W. Gilchrist, T. E. Davis, David W. Westring, Leslie H. Blumgart and Paul Elson and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Dennis L. Citrin

56 papers receiving 1.3k citations

Peers

Countries citing papers authored by Dennis L. Citrin

Since Specialization

Citations

This map shows the geographic impact of Dennis L. Citrin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dennis L. Citrin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dennis L. Citrin more than expected).

Fields of papers citing papers by Dennis L. Citrin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dennis L. Citrin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dennis L. Citrin. The network helps show where Dennis L. Citrin may publish in the future.

Co-authorship network of co-authors of Dennis L. Citrin

This figure shows the co-authorship network connecting the top 25 collaborators of Dennis L. Citrin. A scholar is included among the top collaborators of Dennis L. Citrin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dennis L. Citrin. Dennis L. Citrin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Testicular Pain and Mesenteric Adenitis as an Atypical Presentation of COVID-19 2021 ·Cureus ·(unknown), Dennis L. Citrin, (unknown)	2
2	Prolonged Self-Resolving Neutropenia Following Asymptomatic COVID-19 Infection 2021 ·Cureus ·(unknown), (unknown), Dennis L. Citrin	5
3	Can Long-Standing GnRH Therapy Cause a Pituitary Prolactinoma? 2021 ·Journal of the Endocrine Society ·(unknown), (unknown), (unknown), Janice L Gilden, Dennis L. Citrin	0
4	Treatment of Patients With Lobular Breast Cancer Harboring Human Epidermal Growth Factor Receptor 2 Mutation With HER2-Directed Therapy 2018 ·JCO Precision Oncology ·Dennis L. Citrin, (unknown), (unknown), (unknown), Siraj M. Ali, Ankur R. Parikh, Maurie Markman, Jeffrey S. Ross, (unknown), (unknown)	1
5	How can nurses best help women facing breast cancer? 2016 ·Dennis L. Citrin, (unknown)	0
6	EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer 2015 ·Journal of Clinical Oncology ·Denise A. Yardley, Robert Weaver, Michelle Melisko, Mansoor N. Saleh, Francis P. Arena, Andres Forero, Tessa Cigler, Alison Stopeck, Dennis L. Citrin, Ira A. Oliff, (unknown), Randa Loutfi, Agustin A. García, Scott Cruickshank, Elizabeth Crowley, Jennifer Green, Thomas Hawthorne, Michael Yellin, Thomas A. Davis, Linda T. Vahdat	145
7	Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy 2008 ·Journal of Clinical Oncology ·Stephen Johnston, Maureen Trudeau, Bella Kaufman, Hamouda Boussen, (unknown), Patricia LoRusso, Donald P. Lombardi, Slim Ben Ahmed, Dennis L. Citrin, Michelle DeSilvio, Jennifer L. Harris, Ron E. Westlund, Vanessa Salazar, Tal Zaks, Neil L. Spector	152
8	Phase II Evaluation of Menogaril in Advanced Prostate Cancer 2001 ·American Journal of Clinical Oncology ·Coleman K. Obasaju, Judith Manola, Gary R. Hudes, Janardan D. Khandekar, Dennis L. Citrin, Paul P. Carbone, Donald L. Trump	1
9	Phase II Pilot Study of Combined Chemohormonal Therapy With Doxorubicin and Estramustine in Metastatic Prostate Cancer 2000 ·American Journal of Clinical Oncology ·Naomi B. Haas, Judith Manola, Gary R. Hudes, Dennis L. Citrin, Merrill S. Kies, Thomas E. Davis	12
10	A comparison of Zoladex® and DES in the treatment of advanced prostate cancer: Results of a randomized, multicenter trial 1991 ·The Prostate ·Dennis L. Citrin, Martin I. Resnick, Patrick Guinan, (unknown), Mark Scott, (unknown), Gerard T. Kennealey	28
11	Adrenal cortical carcinoma: Flow cytometricstudy of 22 cases, an ECOG study 1991 ·Urology ·Patricia M. Camuto, Roger Schinella, Kennedy W. Gilchrist, Dennis L. Citrin, George M. Fredrickson	11
12	A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy 1990 ·Investigational New Drugs ·Donald L. Trump, John C. Marsh, Larry K. Kvols, Dennis L. Citrin, Thomas E. Davis, Richard G. Hahn, Steven E. Vogl	31
13	Influence of non-specific immunologic factors on prognosis in advanced bronchogenic carcinoma 1982 ·Cancer Immunology Immunotherapy ·A.M. Liberati, Joseph G. Voelkel, Ernest C. Borden, Alan S. Coates, Dennis L. Citrin, G T Bryan	2
14	Iv dichloromethylene diphosphonate in cancer-associated hypercalcemia: a phase I-II evaluation. 1981 ·PubMed ·(unknown), Jim M. Koeller, T. E. Davis, Dennis L. Citrin	24
15	Atlas of technetium bone scans 1977 ·Saunders eBooks ·Dennis L. Citrin, James H. McKillop	11
16	A Clinical Comparison of 99mTc-Hydroxyethylidene Diphosphonate (H.E.D.P.) and 99mTc-Pyrophosphate in the Detection of Bone Metastases 1977 ·Clinical Nuclear Medicine ·I. Fogelman, James H. McKillop, Dennis L. Citrin	3
17	An assessment of the clinical usefulness of plasma ribonuclease assays 1976 ·Clinica Chimica Acta ·Alan Shenkin, Dennis L. Citrin, R. M. Rowan	19
18	The application of the 99Tcm phosphate bone scan to the study of breast cancer 1975 ·British journal of surgery ·Dennis L. Citrin, R. G. Bessent, W. R. Greig, (unknown), C. M. Furnival, Leslie H. Blumgart	41
19	QUANTITATIVE BONE SCANNING: A METHOD FOR ASSESSING RESPONSE OF BONE METASTASES TO TREATMENT 1974 ·The Lancet ·Dennis L. Citrin, (unknown), R. G. Bessent, W. R. Greig, Leslie H. Blumgart	24
20	Cardiac standstill due to digoxin poisoning successfully treated with atrial pacing. 1973 ·BMJ ·Dennis L. Citrin, K O'Malley, W S Hillis	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact